Literature DB >> 21308776

DLK1 is a novel regulator of bone mass that mediates estrogen deficiency-induced bone loss in mice.

Basem M Abdallah1, Nicholas Ditzel, Amer Mahmood, Adiba Isa, Gunnhildur A Traustadottir, Arndt F Schilling, María-José Ruiz-Hidalgo, Jorge Laborda, Michael Amling, Moustapha Kassem.   

Abstract

Delta-like 1/fetal antigen 1 (DLK1/FA-1) is a transmembrane protein belonging to the Notch/Delta family that acts as a membrane-associated or a soluble protein to regulate regeneration of a number of adult tissues. Here we examined the role of DLK1/FA-1 in bone biology using osteoblast-specific Dlk1-overexpressing mice (Col1-Dlk1). Col1-Dlk1 mice displayed growth retardation and significantly reduced total body weight and bone mineral density (BMD). Micro-computed tomographis (µCT) scanning revealed a reduced trabecular and cortical bone volume fraction. Tissue-level histomorphometric analysis demonstrated decreased bone-formation rate and enhanced bone resorption in Col1-Dlk1 mice compared with wild-type mice. At a cellular level, Dlk1 markedly reduced the total number of bone marrow (BM)-derived colony-forming units fibroblasts (CFU-Fs), as well as their osteogenic capacity. In a number of in vitro culture systems, Dlk1 stimulated osteoclastogenesis indirectly through osteoblast-dependent increased production of proinflammatory bone-resorbing cytokines (eg, Il7, Tnfa, and Ccl3). We found that ovariectomy (ovx)-induced bone loss was associated with increased production of Dlk1 in the bone marrow by activated T cells. Interestingly, Dlk1(-/-) mice were significantly protected from ovx-induced bone loss compared with wild-type mice. Thus we identified Dlk1 as a novel regulator of bone mass that functions to inhibit bone formation and to stimulate bone resorption. Increasing DLK1 production by T cells under estrogen deficiency suggests its possible use as a therapeutic target for preventing postmenopausal bone loss.
Copyright © 2011 American Society for Bone and Mineral Research.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21308776     DOI: 10.1002/jbmr.346

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  22 in total

Review 1.  The obesity of bone.

Authors:  Emanuela A Greco; Andrea Lenzi; Silvia Migliaccio
Journal:  Ther Adv Endocrinol Metab       Date:  2015-12       Impact factor: 3.565

2.  Hepatic stellate cell-derived delta-like homolog 1 (DLK1) protein in liver regeneration.

Authors:  Nian-Ling Zhu; Kinji Asahina; Jiaohong Wang; Akiko Ueno; Raul Lazaro; Yuichiro Miyaoka; Atsushi Miyajima; Hidekazu Tsukamoto
Journal:  J Biol Chem       Date:  2012-02-01       Impact factor: 5.157

3.  Estrogen inhibits Dlk1/FA1 production: a potential mechanism for estrogen effects on bone turnover.

Authors:  Basem M Abdallah; Anne-Christine Bay-Jensen; Bhuma Srinivasan; Nadine C Tabassi; Patrick Garnero; Jean-Marie Delaissé; Sundeep Khosla; Moustapha Kassem
Journal:  J Bone Miner Res       Date:  2011-10       Impact factor: 6.741

Review 4.  Pituitary Tumor-Transforming Gene 1/Delta like Non-Canonical Notch Ligand 1 Signaling in Chronic Liver Diseases.

Authors:  Meritxell Perramón; Wladimiro Jiménez
Journal:  Int J Mol Sci       Date:  2022-06-21       Impact factor: 6.208

5.  In vivo impact of Dlx3 conditional inactivation in neural crest-derived craniofacial bones.

Authors:  Olivier Duverger; Juliane Isaac; Angela Zah; Joonsung Hwang; Ariane Berdal; Jane B Lian; Maria I Morasso
Journal:  J Cell Physiol       Date:  2013-03       Impact factor: 6.384

6.  Osteoblasts remotely supply lung tumors with cancer-promoting SiglecFhigh neutrophils.

Authors:  Camilla Engblom; Christina Pfirschke; Rapolas Zilionis; Janaina Da Silva Martins; Stijn A Bos; Gabriel Courties; Steffen Rickelt; Nicolas Severe; Ninib Baryawno; Julien Faget; Virginia Savova; David Zemmour; Jaclyn Kline; Marie Siwicki; Christopher Garris; Ferdinando Pucci; Hsin-Wei Liao; Yi-Jang Lin; Andita Newton; Omar K Yaghi; Yoshiko Iwamoto; Benoit Tricot; Gregory R Wojtkiewicz; Matthias Nahrendorf; Virna Cortez-Retamozo; Etienne Meylan; Richard O Hynes; Marie Demay; Allon Klein; Miriam A Bredella; David T Scadden; Ralph Weissleder; Mikael J Pittet
Journal:  Science       Date:  2017-12-01       Impact factor: 47.728

7.  Sclerostin and Pref-1 have differential effects on bone mineral density and strength parameters in adolescent athletes compared with non-athletes.

Authors:  P K Fazeli; K E Ackerman; L Pierce; G Guereca; M Bouxsein; M Misra
Journal:  Osteoporos Int       Date:  2013-04-12       Impact factor: 4.507

8.  Bu-Shen-Ning-Xin Decoction ameliorated the osteoporotic phenotype of ovariectomized mice without affecting the serum estrogen concentration or uterus.

Authors:  Ling Wang; Xue-Min Qiu; Yu-Yan Gui; Ying-Ping Xu; Hans-Jürgen Gober; Da-Jin Li
Journal:  Drug Des Devel Ther       Date:  2015-08-31       Impact factor: 4.162

9.  Targeted Inactivation of Rin3 Increases Trabecular Bone Mass by Reducing Bone Resorption and Favouring Bone Formation.

Authors:  Mahéva Vallet; Antonia Sophocleous; Anna E Törnqvist; Asim Azfer; Rob Van't Hof; Omar Me Albagha; Stuart H Ralston
Journal:  Calcif Tissue Int       Date:  2021-03-16       Impact factor: 4.333

10.  FA1 Induces Pro-Inflammatory and Anti-Adipogenic Pathways/Markers in Human Myotubes Established from Lean, Obese, and Type 2 Diabetic Subjects but Not Insulin Resistance.

Authors:  Basem M Abdallah; Henning Beck-Nielsen; Michael Gaster
Journal:  Front Endocrinol (Lausanne)       Date:  2013-04-05       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.